Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.02
+0.02 (0.33%)
At close: Dec 5, 2025, 4:00 PM EST
6.02
0.00 (0.00%)
After-hours: Dec 5, 2025, 6:43 PM EST
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$498,463
Profits / Employee
-$2,304,168
Market Cap
125.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
COYA News
- 10 days ago - Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - Business Wire
- 23 days ago - Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update - Business Wire
- 4 weeks ago - Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
- 5 weeks ago - Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares - Business Wire
- 6 weeks ago - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock - Business Wire
- 6 weeks ago - Coya Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire
- 2 months ago - Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - Business Wire
- 2 months ago - Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - PRNewsWire